Giant Cell Arteritis Immediate Management

In a patient aged 50 years or older with new localized headache, scalp tenderness, temporal artery abnormality, jaw or mouth pain with mastication, ischemia-related visual loss, or polymyalgia rheumatica symptoms, treat the presentation as suspected GCA when the overall clinical pattern is compatible. Diagnostic trial criteria required age 50 years or older, inflammatory-marker elevation, cranial or polymyalgia symptoms, and either positive temporal artery biopsy or large-vessel vasculitis on imaging. accessdata fdaaccessdata fda[PDF] 125276Orig1s112 | FDA

Do not defer glucocorticoids while awaiting temporal artery biopsy, vascular ultrasound, or cross-sectional imaging. Immediate glucocorticoid therapy is the treatment of choice in suspected GCA, and prompt treatment is intended to prevent progression to blindness. Nature+1NatureAutomated detection of giant cell arteritis from temporal artery biopsy specimens using deep learning approaches | Scientific ReportsNatureA new era for giant cell arteritis | Eye

At first assessment, specifically document transient or persistent monocular visual symptoms, diplopia, objective visual loss, jaw claudication, focal neurologic symptoms, and pulse or blood-pressure asymmetry. Ischemia-related vision loss is a recognized cranial manifestation in GCA diagnostic criteria and should move the patient into an emergency treatment pathway rather than an outpatient diagnostic sequence. accessdata fdaaccessdata fda[PDF] 125276Orig1s112 | FDA

Order CRP and ESR at presentation. In one sequential diagnostic analysis, CRP had 86% sensitivity and 56% specificity, while routine ESR had 89% sensitivity and 47% specificity; platelet count had lower sensitivity at 38% but higher specificity at 88%. These tests modify probability but do not independently establish or exclude GCA. ScienceDirectScienceDirectAn update on the clinical approach to giant cell arteritis

Use temporal artery ultrasound when an experienced vascular ultrasonography pathway is immediately available, or obtain temporal artery biopsy when it is the locally established confirmatory test. Imaging and biopsy have similar diagnostic value in proficient hands, but temporal artery ultrasound and MRI identified only 77% and 73%, respectively, of clinically diagnosed cases in cited studies; a negative study therefore does not reliably dismiss a high-probability presentation. BMJBMJ2018 Update of the EULAR recommendations for the management ...

If temporal artery biopsy is chosen, obtain an arterial specimen at least 1 cm in length, corresponding to at least 0.7 cm after fixation. Routine contralateral biopsy is not recommended because it does not significantly increase diagnostic yield. BMJBMJ2018 Update of the EULAR recommendations for the ...

For suspected extracranial or large-vessel disease, obtain angiographic imaging to identify large-vessel vasculitis; this is an accepted diagnostic evidence pathway in addition to temporal artery biopsy. In a patient with persistent high clinical suspicion after negative ultrasound, MRI, or biopsy, pursue a second diagnostic modality rather than stopping therapy solely on one negative test. accessdata fda+1accessdata fda[PDF] 125276Orig1s112 | FDABMJ2018 Update of the EULAR recommendations for the management ...

Glucocorticoids remain the mainstay of initial GCA treatment because they control headache and systemic inflammation and normalize inflammatory markers. Initiate them promptly in clinically suspected disease, then tailor the route and intensity to cranial ischemic risk rather than waiting for pathology. NEJM+2NEJMTrial of Tocilizumab in Giant-Cell ArteritisNatureAutomated detection of giant cell arteritis from temporal artery biopsy specimens using deep learning approaches | Scientific ReportsNatureA new era for giant cell arteritis | Eye

For patients with cranial ischemic manifestations, including visual symptoms or ischemia-related vision loss, use an emergency high-dose glucocorticoid strategy. Trials of initial intravenous methylprednisolone have used 15 mg/kg daily for 3 days followed by oral prednisone 40 mg/day, but the evidence base does not define one optimal induction dose, route, taper, or total duration. BMJ+1BMJfocus on giant cell - RMD OpenNatureA new era for giant cell arteritis | Eye

In patients without ischemic visual symptoms, oral high-dose glucocorticoid therapy is generally used promptly. Randomized comparisons of intravenous versus oral induction in nonischemic presentations have not demonstrated a consistent advantage for intravenous induction, and one larger trial found no difference in disease course over follow-up. NatureNatureThe spectrum of giant cell arteritis through a rheumatology lens | Eye

Reassess symptoms at each contact during induction, particularly headache, jaw claudication, visual symptoms, polymyalgia symptoms, and new large-vessel manifestations. ESR and CRP are useful baseline measures, but treatment response and relapse assessment cannot rely exclusively on acute-phase reactants, particularly after IL-6 pathway inhibition. accessdata fda+2accessdata fda[PDF] 125276Orig1s112 | FDABMJ2018 Update of the EULAR recommendations for the ...BMJfocus on giant cell arteritis | RMD Open

Tocilizumab is FDA-indicated for adult GCA. The labeled regimen is 162 mg subcutaneously once weekly with a tapering glucocorticoid course; 162 mg every other week may be selected on clinical grounds. Tocilizumab may be continued as monotherapy after glucocorticoids are discontinued. accessdata fdaaccessdata fdaACTEMRA (tocilizumab) injection - accessdata.fda.gov

Before initiating tocilizumab, evaluate for tuberculosis according to labeling and monitor for infection during and after therapy, including active tuberculosis despite a negative baseline latent-tuberculosis test. Monitor for dose-related laboratory abnormalities, including elevated liver enzymes, neutropenia, and thrombocytopenia. accessdata fdaaccessdata fdaACTEMRA (tocilizumab) injection - accessdata.fda.gov

Upadacitinib is FDA-indicated for adults with GCA at 15 mg orally once daily with a tapering corticosteroid course and may be used as monotherapy after corticosteroid discontinuation. The label states that no dosage adjustment is needed for mild, moderate, or severe renal impairment in GCA. accessdata fdaaccessdata fdarinvoq/rinvoq lq - accessdata.fda.gov

Methotrexate is a potential glucocorticoid adjunct, and systematic review evidence identifies both methotrexate and tocilizumab as therapies that reduce relapse rates when added to glucocorticoids. In immediate management, choose a steroid-sparing agent after stabilization based on infection risk, laboratory monitoring capacity, comorbidity, medication interactions, and the need to reduce cumulative glucocorticoid exposure. JAMA+1JAMAPolymyalgia Rheumatica and Giant Cell Arteritis: A Systematic ReviewBMJfocus on giant cell arteritis | RMD Open

At every early follow-up, assess for new headache, scalp tenderness, jaw claudication, visual disturbance, visual loss, polymyalgia symptoms, focal neurologic symptoms, constitutional symptoms, and treatment toxicity. Clinical trials evaluated GCA signs and symptoms at every study visit, including headache, jaw pain, PMR/myalgia, and joint pains. accessdata fdaaccessdata fda[PDF] 125276Orig1s112 | FDA

For a patient receiving tocilizumab, interpret normalization of ESR or CRP cautiously because IL-6 pathway inhibition directly affects acute-phase reactants. In the upadacitinib GCA study endpoint, sustained complete remission required absence of GCA signs and symptoms plus protocol-defined normal ESR and hsCRP from week 12 through week 52, illustrating that objective markers and symptom assessment were both incorporated rather than treating either alone as sufficient. accessdata fdaaccessdata fdarinvoq/rinvoq lq - accessdata.fda.gov

New visual or neurologic ischemic symptoms after therapy initiation are not routine outpatient relapse complaints: urgently reassess the diagnosis, treatment adherence, active arterial ischemia, and need for emergency high-dose glucocorticoid management. A negative prior ultrasound, MRI, or biopsy should not prevent reevaluation if the clinical syndrome is compelling. BMJ+2BMJ2018 Update of the EULAR recommendations for the management ...NatureAutomated detection of giant cell arteritis from temporal artery biopsy specimens using deep learning approaches | Scientific ReportsNatureA new era for giant cell arteritis | Eye

For large-vessel disease, retain longitudinal attention to aortic complications. GCA can involve the aorta and subclavian or carotid branches and may lead to aneurysm, rupture, or dissection; use vascular imaging when clinical findings suggest extracranial arterial involvement. Nature+1NatureAutomated detection of giant cell arteritis from temporal artery biopsy specimens using deep learning approaches | Scientific ReportsScienceDirectUse of Noninvasive Imaging in Giant Cell Arteritis